---
title: Continuous infusion reduces wearing off
nct_id: NCT06965374
status: RECRUITING
sponsor: AbbVie
study_type: OBSERVATIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT06965374"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06965374"
last_fetched: "2026-05-10T14:07:49.416Z"
source: "Parkinson's Pathways (curated)"
---
# Continuous infusion reduces wearing off

**Goal (in five words):** Continuous infusion reduces wearing off

**Official Title:** Foslevodopa/Foscarbidopa REal-world Evidence in Parkinson's Disease Quality of LIFE Outcomes

**Trial ID:** [NCT06965374](https://clinicaltrials.gov/study/NCT06965374)

## Key Facts

- **Status:** RECRUITING
- **Study Type:** OBSERVATIONAL
- **Sponsor:** AbbVie
- **Target Enrollment:** 270 participants
- **Start Date:** 2025-06-04
- **Completion Date:** 2027-06
- **Conditions:** Parkinson Disease

## Summary For Families

The goal is to collect real-world quality-of-life data on people with levodopa-responsive advanced Parkinson's who are starting 24-hour subcutaneous foslevodopa/foscarbidopa. Foslevodopa and foscarbidopa are water-soluble prodrugs given as a continuous under-the-skin infusion that convert into levodopa and carbidopa in the body, providing steadier dopamine levels to reduce off time and motor fluctuations compared with intermittent oral dosing. The study is for adults 18 and older whose clinician has already decided to prescribe 24-hour subcutaneous LDp/CDp, excluding anyone with label contraindications, certain skin conditions, or recent participation in an investigational drug trial.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

* Participants with a diagnosis of levodopa-responsive advance Parkinson's disease (PD)
* Investigator decision on participant treatment with subcutaneous Foslevodopa/Foscarbidopa (LDp/CDp) made prior to, and independently, the decision to approach the participant to participate in the study
* 24-h subcutaneous LDp/CDp treatment prescribed in accordance with the applicable approved label and local regulatory and reimbursement policies

Exclusion Criteria:

* Any condition included in the contraindications section of the approved local subcutaneous LDp/CDp label
* Participation in a clinical trial of an investigational drug, concurrently or within the last 30 days. Participation in another Post-Marketing Observational Study (PMOS) or Registry is acceptable
* History of relevant skin conditions or disorders (e.g., psoriasis, atopic dermatitis) per investigator´s judgment. In case of temporary affections like recent sunburn, acne, scar tissue, tattoo, open wound, branding, or colorations, the subject should not be included if the investigator considers these as interfering with the infusion of study drug or with study assessments
```

## Locations (19)

- IRCCS Oasi SS. Troina /ID# 273507, Troina, Enna, Italy _(37.7844, 14.5960)_
- Istituto Neurologico Mediterraneo Neuromed S.P.A. - Irccs /Id# 272695, Pozzilli, Isernia, Italy _(41.5114, 14.0625)_
- ASST Centro Specialistico Ortopedico Traumatologico Gaetano Pini-CTO /ID# 272949, Milan, Milano, Italy _(45.4643, 9.1895)_
- Fondazione IRCCS Istituto Neurologico Carlo Besta /ID# 273225, Milan, Milano, Italy _(45.4643, 9.1895)_
- Azienda Ospedaliera Universitaria Luigi Vanvitelli /ID# 273434, Naples, Napoli, Italy _(40.8522, 14.2681)_
- A.O.U. CITTA' DELLA SALUTE E DELLA SCIENZA DI TORINO - Ospedale Molinette /ID# 273276, Turin, Piedmont, Italy _(45.0705, 7.6868)_
- Azienda Ospedaliera Universitaria Policlinico Tor Vergata /ID# 272834, Rome, Roma, Italy _(41.8919, 12.5113)_
- Azienda Ospedaliero-Universitaria Policlinico Umberto I /ID# 273562, Rome, Roma, Italy _(41.8919, 12.5113)_
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS-Universita Cattolica /ID# 274539, Rome, Roma, Italy _(41.8919, 12.5113)_
- Azienda Ulss 3 Serenissima /ID# 273027, Venice, Venezia, Italy _(45.4371, 12.3326)_
- Azienda Ospedaliero Universitaria delle Marche /ID# 272694, Ancona, Italy _(43.6072, 13.5103)_
- Ospedale Bellaria - Azienda Usl Di Bologna /ID# 274463, Bologna, Italy _(44.4938, 11.3387)_
- IRCCS Centro Neurolesi Bonino Pulejo /ID# 273628, Messina, Italy _(38.1939, 15.5526)_
- Azienda Ospedale-Universita Padova /ID# 274317, Padova, Italy _(44.3822, 11.1426)_
- Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone /ID# 272863, Palermo, Italy _(38.1166, 13.3636)_
- Fondazione Mondino Istituto Neurologico Nazionale a Carattere Scientifico IRCCS /ID# 274226, Pavia, Italy _(45.1921, 9.1592)_
- Azienda Ospedaliero Universitaria Pisana /ID# 273541, Pisa, Italy _(43.7085, 10.4036)_
- AUSL di Reggio Emilia - Arcispedale Santa Maria Nuova /ID# 274388, Reggio Emilia, Italy _(44.6983, 10.6312)_
- AOU San Giovanni di Dio Ruggi d'Aragona - Scuola Medica Salernitana /ID# 274319, Salerno, Italy _(40.6754, 14.7933)_

## Central Contacts

- Caterina Golotta — (CONTACT) — +39 06 548891 — caterina.golotta@abbvie.com

---

*Canonical: https://parkinsonspathways.com/trial/NCT06965374*  
*HTML version: https://parkinsonspathways.com/trial/NCT06965374*  
*Source data: https://clinicaltrials.gov/study/NCT06965374*